Meeting
2016 ASCO Annual Meeting
SOLO3: A randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm).
Authors
Elizabeth S. Lowe
AstraZeneca, Gaithersburg, MD
Elizabeth S. Lowe , Deepthi Jayawardene , Richard T. Penson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02282020
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS5598)
DOI
10.1200/JCO.2016.34.15_suppl.TPS5598
Abstract #
TPS5598
Poster Bd #
420b
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).
First Author: Talia Golan
Poster
2023 ASCO Annual Meeting
Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.
First Author: Philipp Harter
Poster
2018 ASCO Annual Meeting
Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials.
First Author: Kirsten Timms
Poster
2015 ASCO Annual Meeting
POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (gBRCAm) who have not progressed following first-line chemotherapy.
First Author: Hedy Lee Kindler